Press release
Follicular Lymphoma Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED
The Follicular Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Follicular Lymphoma Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Follicular Lymphoma Market.
Some of the key takeaways from the Follicular Lymphoma Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Follicular Lymphoma treatment therapies with a considerable amount of success over the years.
*
Follicular Lymphoma companies working in the treatment market are InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharmaceuticals, ADC Therapeutics, AstraZeneca, Dr Reddy's Laboratories, MAB WORKS, and others, are developing therapies for the Follicular Lymphoma treatment
*
Emerging Follicular Lymphoma therapies in the different phases of clinical trials are- ICP 248, ALLO-501, HMPL-689, PSB 202, Abexinostat, Loncastuximab tesirine, Acalabrutinib, DRL_RI, MIL62, and others are expected to have a significant impact on the Follicular Lymphoma market in the coming years.
*
In February 2024, The FDA has granted Priority Review to AbbVie and Genmab's Epkinly (epcoritamab) for a supplemental biologics license application (sBLA) aimed at treating difficult-to-treat relapsed or refractory (r/r) follicular lymphoma (FL), a slow-growing type of lymphoma, after at least two prior lines of systemic therapy. Despite the emergence of new treatments and chimeric antigen receptor (CAR)-T cell therapy, there remains a substantial unmet need for managing r/r FL with effective and more convenient therapies, which Epkinly aims to address.
*
IN November 2023, Bayer, a multinational pharmaceutical company based in Germany, has revealed intentions to voluntarily retract its new drug application in the United States for Aliqopa (copanlisib) in the treatment of relapsed follicular lymphoma (FL) due to an unsuccessful trial. This determination follows discussions between the company and the US Food and Drug Administration (FDA) regarding the trial data for Aliqopa's efficacy.
Follicular Lymphoma Overview
Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma (NHL), a cancer that originates in the lymphatic system, which is part of the body's immune system. FL specifically arises from abnormal B-lymphocytes, a type of white blood cell, and typically grows slowly over time.
Get a Free Sample PDF Report to know more about Follicular Lymphoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight [https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Follicular Lymphoma Drugs Under Different Phases of Clinical Development Include:
*
ICP 248: InnoCare Pharma
*
ALLO-501: Allogene Therapeutics
*
HMPL-689: HUTCHMED
*
PSB 202: Sound Biologics
*
Abexinostat: Xynomic Pharmaceuticals
*
Loncastuximab tesirine: ADC Therapeutics
*
Acalabrutinib: AstraZeneca
*
DRL_RI: Dr Reddy's Laboratories
*
MIL62: MAB WORKS
Follicular Lymphoma Route of Administration
Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Intra-articular
*
Intraocular
*
Intrathecal
*
Intravenous
*
Ophthalmic
*
Oral
*
Parenteral
*
Subcutaneous
*
Topical
*
Transdermal
Follicular Lymphoma Molecule Type
Follicular Lymphoma Products have been categorized under various Molecule types, such as
*
Oligonucleotide
*
Peptide
*
Small molecule
Follicular Lymphoma Pipeline Therapeutics Assessment
*
Follicular Lymphoma Assessment by Product Type
*
Follicular Lymphoma By Stage and Product Type
*
Follicular Lymphoma Assessment by Route of Administration
*
Follicular Lymphoma By Stage and Route of Administration
*
Follicular Lymphoma Assessment by Molecule Type
*
Follicular Lymphoma by Stage and Molecule Type
DelveInsight's Follicular Lymphoma Report covers around 50+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Follicular Lymphoma product details are provided in the report. Download the Follicular Lymphoma pipeline report to learn more about the emerging Follicular Lymphoma therapies [https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Follicular Lymphoma Therapeutics Market include:
Key companies developing therapies for Follicular Lymphoma are - Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, ADC Therapeutics, Incyte Corporation, MorphoSys, AbbVie, Janssen Research & Development, Regeneron Pharmaceuticals, Novartis, MEI Pharma, BeiGene, Xynomic Pharmaceuticals, Bristol Myers Squibb, and others.
Follicular Lymphoma Pipeline Analysis:
The Follicular Lymphoma pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Follicular Lymphoma with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Follicular Lymphoma Treatment.
*
Follicular Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Follicular Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Follicular Lymphoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Follicular Lymphoma drugs and therapies [https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Follicular Lymphoma Pipeline Market Drivers
*
Increase in prevalence of Follicular Lymphoma, emergence of effective novel therapies, increased Research and Developmental Activities are some of the important factors that are fueling the Follicular Lymphoma Market.
Follicular Lymphoma Pipeline Market Barriers
*
However, lack Of Cost-Effective Treatment, progression of disease within 2 years (POD24) in the Disease and other factors are creating obstacles in the Follicular Lymphoma Market growth.
Scope of Follicular Lymphoma Pipeline Drug Insight
*
Coverage: Global
*
Key Follicular Lymphoma Companies: InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Biologics, Xynomic Pharmaceuticals, ADC Therapeutics, AstraZeneca, Dr Reddy's Laboratories, MAB WORKS, and others
*
Key Follicular Lymphoma Therapies: ICP 248, ALLO-501, HMPL-689, PSB 202, Abexinostat, Loncastuximab tesirine, Acalabrutinib, DRL_RI, MIL62, and others
*
Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies
*
Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers
Request for Sample PDF Report for Follicular Lymphoma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Follicular Lymphoma Report Introduction
2. Follicular Lymphoma Executive Summary
3. Follicular Lymphoma Overview
4. Follicular Lymphoma- Analytical Perspective In-depth Commercial Assessment
5. Follicular Lymphoma Pipeline Therapeutics
6. Follicular Lymphoma Late Stage Products (Phase II/III)
7. Follicular Lymphoma Mid Stage Products (Phase II)
8. Follicular Lymphoma Early Stage Products (Phase I)
9. Follicular Lymphoma Preclinical Stage Products
10. Follicular Lymphoma Therapeutics Assessment
11. Follicular Lymphoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Follicular Lymphoma Key Companies
14. Follicular Lymphoma Key Products
15. Follicular Lymphoma Unmet Needs
16 . Follicular Lymphoma Market Drivers and Barriers
17. Follicular Lymphoma Future Perspectives and Conclusion
18. Follicular Lymphoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=follicular-lymphoma-pipeline-and-clinical-trials-assessment-2024-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-astrazeneca-innocare-pharma-allogene-therapeutics-hutchmed]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Follicular Lymphoma Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED here
News-ID: 3506627 • Views: …
More Releases from ABNewswire
From Fields to Frontlines: 4 Drone Firms Defining a $555 Billion Future
The global drone services market is projected to soar from around $33 billion in 2025 to over $555 billion by 2034, a staggering 16-fold increase fueled by breakthroughs in AI, autonomous systems, and data analytics. Investors looking for the next big wave in technology and defense should pay close attention: drones have evolved from niche gadgets to essential tools reshaping agriculture, logistics, infrastructure, and national security.
But this isn't just a…
Roxanne Luciano Turns Heartbreak Into Heat with New Single "You My Ex"
Rising hip-hop sensation Roxanne Luciano has dropped her latest single, "You My Ex," a fearless breakup anthem that redefines closure with unapologetic confidence.
The track blends hard-hitting production with Roxanne's commanding vocal delivery, embodying both strength and sensuality. With magnetic energy and undeniable stage presence, Roxanne is setting a new standard for hip-hop artistry rooted in beauty, edge, and authenticity. "This record is for anyone who's done settling for less," says…
Couples Counseling DC: When to Seek Help and What to Expect with Keith Miller Co …
Many couples in Washington, DC feel disconnected without knowing why. This blog explores the right time to seek couples counseling and what actually happens in sessions at Keith Miller Counseling. With real-world insight into communication patterns, emotional safety, and long-term connection, readers learn how therapy can become a turning point-not just a last resort.
Relationships don't fall apart overnight. It often starts with small disagreements, emotional distance, or a feeling that…
Vero Beach Wellness Entrepreneur Tricia Snow Pioneers Red Light Therapy Transfor …
Vero Beach, FL - Wellness visionary Tricia Snow, founder of RED Vero, is redefining how Vero Beach residents experience beauty, healing, and body transformation through cutting-edge red light therapy. Located at 1850 43rd Avenue, Suite C3, RED Vero combines science-backed technology with a holistic approach to help clients look and feel their best - from skin rejuvenation and fat loss to pain relief and cellular recovery.
"At RED Vero, we believe…
More Releases for Follicular
Key Trends Reshaping the Follicular Lymphoma Treatment Market: Technological Adv …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Follicular Lymphoma Treatment Market Size Growth Forecast: What to Expect by 2025?
In recent years, there has been robust growth in the size of the follicular lymphoma treatment market. The market is projected to expand from $3.05 billion in 2024 to $3.28 billion in 2025, with a compound annual…
Follicular Lymphoma Market to Reach USD 6.74 Billion by 2034
Follicular lymphoma (FL) is the second most common type of non-Hodgkin lymphoma (NHL), accounting for roughly 20-30% of NHL cases worldwide. It is generally an indolent (slow-growing) B-cell malignancy, but it can transform into aggressive lymphoma in some patients. With advancements in immunotherapy, monoclonal antibodies, and targeted therapies, treatment outcomes have improved, offering patients longer remission periods and better quality of life.
Download Full PDF Sample Copy of Market Report @…
Follicular Lymphoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Follicular Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 50+ Follicular Lymphoma companies and 50+ pipeline drugs in the Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Follicular Lymphoma Pipeline Insights Report 2024
DelveInsight's, "Follicular Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 50+ Follicular Lymphoma companies and 50+ pipeline drugs in the Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Global Follicular Lymphoma Treatment Industry Opportunities, Analysis & Forecast …
Dhirtek Business Research and Consulting most recent study on the follicular lymphoma treatment market provides a comprehensive view of the entire market. The research report delves deeply into the global follicular lymphoma treatment market's drivers and restraints. Analysts have extensively researched the global follicular lymphoma treatment market's milestones and the current trends that are expected to determine its future. Primary and secondary research methods were used to create an in-depth…
Follicular Unit Extraction (FUE) Systems Market 2021 | Detailed Report
ReportsnReports publishes the report titled Follicular Unit Extraction (FUE) Systems that presents a 360-degree overview of the market under one roof. The report is developed with the meticulous efforts of an enthusiastic and experienced team of experts, analyts, and researchers that makes the report a valuable asset for stakeholders to make robust decisions. This report also provides an in-depth overview of product type, specification, technology, and production analysis considering vital…
